Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1L | O00429 | 14/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3020267 | 0.94 | DNM1L (0.33) | DNM1LNR3C1PGRNR3C2MEN1 | |
| SCHEMBL3002261 | 0.92 | DNM1L (0.38) | DNM1LMEN1KMT2AHRH3 | |
| SCHEMBL3013715 | 0.90 | DNM1L (0.35) | DNM1LHRH3MAPK1 | |
| SCHEMBL3018927 | 0.89 | DNM1L (0.36) | DNM1LNR3C1PGRNR3C2MEN1 | |
| SCHEMBL3016483 | 0.88 | SMN1; SMN2 (0.39) | DNM1LMEN1KMT2AHRH3 | |
| SCHEMBL3018251 | 0.88 | HRH3 (0.34) | DNM1LHRH3MAPK1 | |
| SCHEMBL3007844 | 0.88 | CACNA1G (0.36) | DNM1LMEN1KMT2AHRH3LMNA | |
| SCHEMBL3008362 | 0.87 | DNM1L (0.42) | DNM1LMEN1KMT2ALMNAMAPK1 | |
| SCHEMBL3017445 | 0.87 | MEN1 (0.40) | DNM1LMEN1KMT2AHRH3 | |
| SCHEMBL3012903 | 0.87 | F2RL3 (0.37) | DNM1LHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8722681-B2 | N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases | NV REMYND (BE) | 2014-05-13 | — | — | US | disclosed |
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | NV REMYND (BE) | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197703-A1 | N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES | SMN1; SMN2, HTT, SNCA | DNM1L 180/4885NR3C1 1581/4885PGR 4627/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.